Cancer research
Advances in VEGF Pathway-Targeted Therapy Show Promise for Renal Cancer Treatment
Researchers at the Chicago Medical Center have highlighted the advancements in understanding the association between the von Hippel-Lindau pathway and angiogenesis in the development of renal cancer. This breakthrough has led to the development of highly effective vascular endothelial growth factor (VEGF) pathway-targeted inhibitors, which have demonstrated increased clinical benefit,